{"name":"IO Biotech","slug":"io-biotech","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"IO102-IO103","genericName":"IO102-IO103","slug":"io102-io103","indication":"Melanoma (adjuvant setting)","status":"phase_3"}]}],"pipeline":[{"name":"IO102-IO103","genericName":"IO102-IO103","slug":"io102-io103","phase":"phase_3","mechanism":"IO102-IO103 is a personalized neoantigen vaccine designed to activate the immune system against patient-specific tumor mutations.","indications":["Melanoma (adjuvant setting)","Non-small cell lung cancer (adjuvant setting)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFB1N2d4NnYwN0JiU181Tm9vV0dUM1c1NWVMUHNCdlZFVmRSZXpmRFp3TnBQUVJXYnFYV1VlNVBIZXU0TzY4bE5BNTd4NGpIT21aYlZHMy1qSW1HWDFH?oc=5","date":"2026-04-06","type":"pipeline","source":"BioSpace","summary":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees - BioSpace","headline":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9PQ2x3emFoSXRraVNQcHEwQmF2OERNYjlESFBpWDh3Q0MxcVlSdURpOXRUcEQ5TzBBQmJXT19YcmF5YUZjekFfMEtXRWRWM1RQUEFZ?oc=5","date":"2026-04-01","type":"pipeline","source":"FirstWord Pharma","summary":"Biopharma bites: Axsome adds an asset from Takeda, IO Biotech's farewell, and Evotec's new commercial leader - FirstWord Pharma","headline":"Biopharma bites: Axsome adds an asset from Takeda, IO Biotech's farewell, and Evotec's new commercial leader","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQOVdVQ05fdHdxVVhMUWdpUm1PeS1JdWx4ZHl2UUZGWlVLQjkzNV9Qdm9DODZKY2oxWnRfa2NMX1ZMRlZvajYzczF3Tms0aVlVNFljdF9zN1l4SGdoZzlweDUzM3BOT25QY1hpOFJUdWFNTmZ1YUttRUVNeTVTby1wNjRydWFuX3VOOG9DaHBjaV90TTBNYWs2bFR0Z3E?oc=5","date":"2026-03-31","type":"regulatory","source":"Fierce Biotech","summary":"Still reeling from FDA refusal, IO Biotech surrenders to bankruptcy - Fierce Biotech","headline":"Still reeling from FDA refusal, IO Biotech surrenders to bankruptcy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE54YTd6U0Z6bkhSVmR3cEFEd2lESjRaQjRpZU1paTR6T1dmQjVJTFJETkd3UXNSaGdja1NQbDFocDVaZHV0M0NyRThZT2REM1RWYldvMTJQanRiYS00NzEzVTB1Njl1bEpOQ19ST0x6cmUzTlRKZ2pOZDQtNnI?oc=5","date":"2026-03-31","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Layoff Tracker 2026: Lipella, IO shutter; Takeda plots 634 US job cuts - Fierce Biotech","headline":"Fierce Biotech Layoff Tracker 2026: Lipella, IO shutter; Takeda plots 634 US job cuts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE1UZ3QxSlYzU1BENEl0QjNzTy1yQk56SkdjcVE3ZlNvQ2xlQ3lLZHdETm9kODhNeW1BOUM4YWY1QU1XNVJYYjhGdGZyRlZkQkRaYWxuR1JjM1NLcDZJMDFlbHpIcnhaczFBb2hJLU92QQ?oc=5","date":"2026-01-22","type":"regulatory","source":"medwatch.com","summary":"Listed Danish biotech company fights for survival after FDA rejection and failed capital raising - medwatch.com","headline":"Listed Danish biotech company fights for survival after FDA rejection and failed capital raising","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxOd1RvaW55T0ZqRFRQSVdCblFHRXNjM1Zjdl9qcFlOVnRqTXRHeDhBcVZxSGRWSGlQSkoxWVo4Nm9qUXJRUzlNZ2hRRUJ1LWJLS2NjMldwTHdGdUZWaGZRcEZVbkxXM0g3OE4yMFlyLXZaM1ZjTjVhVWN6cEFqeVQ0elpHeDhGRzBxV1FlNFhuRUs1c3JMNWpEUVlEa21fR0t4MjlLWHBkQ3dZYU8zSHM0SWdjVWJ6MEdyand5and3SVZtcHl3dWs2c1MwOVQ3eEUyUmw3VVBjQmY1dm8?oc=5","date":"2025-08-12","type":"trial","source":"Reuters","summary":"IO Biotech's cancer vaccine shows improvement, but narrowly misses study goal - Reuters","headline":"IO Biotech's cancer vaccine shows improvement, but narrowly misses study goal","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPMVh3MHFxODZSZHpoZlc4Y2VRRkFvSnhnblZ3WDFhZTZmWFpvaE01Y2w2QnNaUlJLSUt3MXcxWlh1MFRUa1J2a00yb3cxTUl0SFZnellQYmxPSzNNTzVCQ212aFk4SkYwb2NjcmFqd1RES3RCTUs5QzRnMXBNMDVFX2tUQmtTNEtRV3Fnck1tVEFFaDdGSEZ2ZlVGN2xFcGRoanZaWWNxYXhLalQtUzR3?oc=5","date":"2025-08-12","type":"trial","source":"seekingalpha.com","summary":"IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma - seekingalpha.com","headline":"IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNdm1tRkJyRjk5eGZDT2wzaG95SzR2NFBhbVJEcjVmQ3hvX2FuV2Q2SVBuaDdyMGFCRzR1YzZLQWZrV0t4ZnUtcGlta0tmRk9DeUN2NFZxcUdVWGZWUFFuTWxwbWRRazVodnRnMk9jVVNSOG56S2diOTQyVEVKRDBnTzN0UHNBeGRtNGlFa0FPMHpwazBuUkptZEVoVmFaNXFIbkE?oc=5","date":"2025-08-11","type":"trial","source":"BioPharma Dive","summary":"IO Biotech sees path forward for skin cancer vaccine despite study setback - BioPharma Dive","headline":"IO Biotech sees path forward for skin cancer vaccine despite study setback","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQSlBmek02NVEwdnZPS3pvTnQ0UkdjRjFFai1qdGdWV3RVWVFJck1mVTBPbTRucm95U2ViWm8xUmREUWJMU2ZSN2dFQXQ2QUptalZTNGZtbHpvbWNSVDZNQmRzVGpNZm52Q3paZ3BRZXk4b0ZaTWxGUXNtNWpIRjU3ZlVaVTBDVDI5OG9tYzNUd3VubVAwYlE?oc=5","date":"2025-08-11","type":"regulatory","source":"Clinical Trials Arena","summary":"IO Biotech to pursue cancer vaccine approval despite Phase III miss - Clinical Trials Arena","headline":"IO Biotech to pursue cancer vaccine approval despite Phase III miss","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE13aGpFS1B5VmJJQ283SDl3d1ZIN1ZLTGJWNU9lOS1RTXNDdUxFbUl4YVpBNHFYWnZSTElIZUFXamVBdnIzUHRVS2UxOXdtQXBmR1ZHWQ?oc=5","date":"2025-08-11","type":"pipeline","source":"The Pharma Letter","summary":"IO Biotech - The Pharma Letter","headline":"IO Biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQV3V1Q2ZlbWVROFVINEZtalVwQV9nMFZ1ZWV2SWFJSHdtalhIaFlYQ1dYeTJsM0FCQ3BXWGRDVFp6cHB3RVFxMlp4RnBEVXF1enFtNGNLU3NlQ1Vtb0VLT0RjazRLa2wySHczRDZrLXU3dkJxY0ZtT1JZQVotRlZ4b24xdw?oc=5","date":"2025-07-16","type":"pipeline","source":"Yahoo Finance","summary":"Private equity firms are IO Biotech, Inc.'s (NASDAQ:IOBT) biggest owners and were rewarded after market cap rose by US$16m last week - Yahoo Finance","headline":"Private equity firms are IO Biotech, Inc.'s (NASDAQ:IOBT) biggest owners and were rewarded after market cap rose by US$1","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-16","type":"pipeline","source":"simplywall.st","summary":"IO Biotech, Inc.'s (NASDAQ:IOBT) largest shareholders are private equity firms who were rewarded as market cap surged US$16m last week - simplywall.st","headline":"IO Biotech, Inc.'s (NASDAQ:IOBT) largest shareholders are private equity firms who were rewarded as market cap surged US","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}